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Simple and efficient synthesis of 2-(1,2,4-oxadiazol-5-yl)-2,3-dihydro-4H-chromen-4-ones is 
elaborated. The method relies on CDI-mediated cyclocondensation of substituted 4-oxochromane-2-
carboxylic acids and amidoximes. The protocol allows the preparation of 2-oxadiazolylchromanones 
decorated with two pharmacophores (2,3-dihydro-4H-chromen-4-one and 1,2,4-oxadiazole) that are 
in high demand in drug discovery. 
________________________________________________________________________________ 
Introduction 
Chromones are on demand in the 
chemical community since their high abundance 
in natural products and medicines [1, 2]. 
Compound bearing this core are widely used as 
fluorescent probes for adenosine triphosphate 
(ATP) detection [3, 4]. On the other hand, 
chromanones – saturated derivatives of parent 
chromones – gained significant interest as 
synthetic intermediates of flavonoids and as 
multipurpose tools with a wide range of 
applications [5, 6]. In particular, chromanones 
are applied as antianxiety [7], anticancer [8, 9], 
anti-inflammatory [9], antibacterial [10] and 
antifungal agents [10 – 14], HIV-1 reverse 
transcriptase inhibitors [15], and as molecular 
switch scaffolds [16].  
Further expansion of the application field 
requires introducing more complex substituents, 
e.g., heterocyclic, into the chromanone molecule 
for purposes of medicinal chemistry and 
agrochemistry. Classical approaches towards the 
synthesis of functionalized flavanones via 
transformations of the corresponding chalcones 
have many limitations for the synthesis of 2-
heteroaryl substituted chromanones [6]. Much 
effort has been made to find alternative methods 
for the synthesis of the aforementioned 
compounds, i.e., the photoredox α-
heteroarylation of 2-trifluoroboratochromanones 
[5] and the enantioselective alkynylation of 
chromones [17]. 
Despite the achieved progress in the 
synthesis of 2-heteroaryl substituted 
chromanones, no methods for the preparation of 
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chromanones bearing C(2)-oxadiazole 
substituent were reported to date. For scientists, 
1,2,4-oxadiazoles are particularly interesting 
because of their presence in various drugs: 
Pleconaril (antiviral), Fasiplon (anxiolytic), 
Butalamine (vasodilator), Oxolamine (cough 
suppressant) [18]. 
Experimental part 
Solvents were purified according to the 
standard procedures. 1H and 13C NMR spectra 
were recorded on Mercury 400 Varian (at 400.4 
MHz for protons) and Bruker 170 Avance 500 
spectrometer (at 499.9 MHz for Protons and 
124.9 MHz for Carbon-13). Chemical shifts are 
reported in ppm downfield from TMS as an 
internal standard. Elemental analyses were 
performed at the Laboratory of Organic Analysis, 
Department of Chemistry, National Taras 
Shevchenko University of Kyiv. Compounds 1 
were prepared by the same procedures reported 
in ref [19]. Amidoximes 2 were obtained similar 
to the published protocol [20]. 
General procedure for the preparation of 
2-(1,2,4-oxadiazol-5-yl)-2,3-dihydro-4H-
chromen-4-ones 3: 1,1'-carbonyldiimidazole 
(CDI) (0.18 g, 0,0011 mol) was added to a 
solution of substituted 4-oxochromane-2-
carboxylic acid 1 (0,001 mol) in DMF, and the 
resulting mixture was stirred for 30 min at 
ambient temperature. Then corresponding 
amidoxime 2 (0,0011 mol) was added. The 
mixture was stirred at 70 C for 1 h, cooled, and 
the solvent was evaporated in vacuo. The 
obtained residue was recrystallized from aqueous 
ethanol to give product 3 as a beige powder. 
2-[3-(dimethylamino)-1,2,4-oxadiazol-5-
yl]-6-methyl-2,3-dihydro-4H-chromen-4-one 
(3a). Yield 0.194 g, 71 %. Mp 105–106°C. 1H 
NMR (400 MHz, DMSO-d6) δ 7.55 (s, 1H), 7.41 
(d, J = 8.3 Hz, 1H), 7.02 (d, J = 8.3 Hz, 1H), 6.01 
(t, J = 6.3 Hz, 1H), 3.24 – 3.14 (m, 2H), 2.88 (s, 
6H), 2.26 (s, 3H). 13C NMR (125 MHz, DMSO-
d6) δ 189.1, 174.2, 169.9, 157.2, 137.3, 131.4, 
125.8, 120.3, 117.8, 70.4, 39.3, 37.6 (2C), 19.9. 
Anal. Calcd. for C14H15N3O3: C 61.53; H 5.53; N 
15.38. Found: C 61.59; H 5.49; N 15.44. 
2-[3-(dimethylamino)-1,2,4-oxadiazol-5-
yl]-6-fluoro-2,3-dihydro-4H-chromen-4-one 
(3b). Yield 0.205 g, 74 %. Mp 127–128°C. 1H 
NMR (400 MHz, DMSO-d6) δ 7.52 – 7.45 (m, 
2H), 7.21 (dd, J = 8.8, 4.2 Hz, 1H), 6.07 (t, J = 
6.5 Hz, 1H), 3.24 (d, J = 6.5 Hz, 2H), 2.88 (s, 
6H). 13C NMR (125 MHz, DMSO-d6) δ 188.5, 
173.9, 169.9, 157.0 (d, JCF = 239 Hz), 155.53, 
123.9 (d, JCF = 24 Hz), 121.3 (d, JCF = 6 Hz), 
120.2 (d, JCF = 8 Hz), 111.1 (d, JCF = 22 Hz), 
70.58, 39.04, 37.60 (2C). Anal. Calcd. for 
C13H12FN3O3: C 56.32; H 4.36; N 15.16. Found: 
C 56.29; H 4.42; N 15.21. 
2-(3-isopropyl-1,2,4-oxadiazol-5-yl)-6-
methyl-2,3-dihydro-4H-chromen-4-one (3c). 
Yield 0.187 g, 69 %. Mp 68–70°C. 1H NMR (400 
MHz, DMSO-d6) δ 7.56 (s, 1H), 7.42 (d, J = 8.4 
Hz, 1H), 7.04 (d, J = 8.4 Hz, 1H), 6.15 (dd, J = 
7.7, 5.4 Hz, 1H), 3.29 – 3.17 (m, 2H), 3.13 – 2.97 
(m, 1H), 2.26 (s, 3H), 1.22 (d, J = 6.9 Hz, 6H). 
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13C NMR (125 MHz, DMSO-d6) δ 188.9, 175.3, 
174.7, 157.2, 137.4, 131.5, 125.8, 120.3, 117.8, 
70.4, 39.4, 26.1, 20.1, 20.00, 19.9. Anal. Calcd. 
for C15H16N2O3: C 66.16; H 5.92; N 10.29. 
Found: C 66.22; H 5.98; N 10.34. 
6-bromo-2-(3-isopropyl-1,2,4-oxadiazol-
5-yl)-2,3-dihydro-4H-chromen-4-one (3d). Yield 
0.262 g, 78 %. Mp 110–111°C. 1H NMR (400 
MHz, DMSO-d6) δ 7.83 (s, 1H), 7.77 (d, J = 8.8 
Hz, 1H), 7.15 (d, J = 8.8 Hz, 1H), 6.31 – 6.18 (m, 
1H), 3.32 – 3.22 (m, 2H), 3.13 – 2.99 (m, 1H), 
1.23 (d, J = 6.4 Hz, 6H). 13C NMR (125 MHz, 
DMSO-d6) δ 188.2, 174.7, 171.9, 158.1, 137.2, 
129.6, 121.9, 118.4, 113.9, 70.6, 39.8, 27.9, 20.7 
(2C). Anal. Calcd. for C14H13BrN2O3: C 49.87; H 
3.89; N 8.31. Found: C 49.82; H 3.94; N 8.40. 
6-chloro-2-(3-isopropyl-1,2,4-oxadiazol-
5-yl)-2,3-dihydro-4H-chromen-4-one (3e). Yield 
0.240 g, 82 %. Mp 109–110°C. 1H NMR (400 
MHz, DMSO-d6) δ 7.71 (s, 1H), 7.65 (d, J = 9.1 
Hz, 1H), 7.21 (d, J = 9.1 Hz, 1H), 6.24 (dd, J = 
7.5, 4.0 Hz, 1H), 3.32 – 3.21 (m, 2H), 3.13 – 2.98 
(m, 1H), 1.22 (d, J = 6.3 Hz, 6H). 13C NMR (125 
MHz, DMSO-d6) δ 188.2, 174.7, 171.9, 158.1, 
137.2, 129.6, 121.9, 118.4, 113.9, 70.6, 39.8, 
27.9, 20.7 (2C). Anal. Calcd. for C14H13ClN2O3: 
C 57.44; H 4.48; N 9.57. Found: C 57.51; H 4.45; 
N 9.60. 
6-fluoro-2-(3-isopropyl-1,2,4-oxadiazol-
5-yl)-2,3-dihydro-4H-chromen-4-one (3f). Yield 
0.201 g, 73 %. Mp 83–85°C. 1H NMR (400 MHz, 
DMSO-d6) δ 7.61 – 7.41 (m, 2H), 7.22 (dd, J = 
8.8, 4.2 Hz, 1H), 6.21 (dd, J = 8.5, 4.8 Hz, 1H), 
3.36 – 3.22 (m, 2H), 3.10 – 3.03 (m, 1H), 1.22 (d, 
J = 6.9 Hz, 6H). ). 13C NMR (125 MHz, DMSO-
d6) δ 188.9, 175.4, 175.1, 157.5 (d, JCF = 242 Hz) 
156.0, 124.4 (d, JCF = 26 Hz), 121.8 (d, JCF = 8 
Hz), 120.7 (d, JCF = 8 Hz), 111.6 (d, JCF = 23 Hz), 
70.9, 39.6, 26.5, 20.6, 20.5. Anal. Calcd. for 
C14H13FN2O3: C 60.87; H 4.74; N 10.14. Found: 
C 60.81; H 4.70; N 10.21. 
6-chloro-7-fluoro-2-(3-isopropyl-1,2,4-
oxadiazol-5-yl)-2,3-dihydro-4H-chromen-4-one 
(3g). Yield 0.202 g, 65 %. Mp 128–129°C. 1H 
NMR (500 MHz, DMSO-d6) δ 7.88 (d, J = 9.8 
Hz, 1H), 7.39 (d, J = 11.5 Hz, 1H), 6.30 – 6.27 
(m, 1H), 3.35 – 3.25 (m, 2H), 3.09 – 3.05 (m, 
1H), 1.23 (d, J = 8.4 Hz, 6H). ). 13C NMR (125 
MHz, DMSO-d6) δ 188.9, 175.4, 175.1, 157.5 (d, 
JCF = 242 Hz) 156.00, 124.4 (d, JCF = 26 Hz), 
121.8 (d, JCF = 8 Hz), 120.7 (d, JCF = 8 Hz), 111.6 
(d, JCF = 23 Hz), 70.9, 39.6, 26.5, 20.6, 20.5. 
Anal. Calcd. for C14H12ClFN2O3: C 54.12; H 
3.89; N 9.02. Found: C 54.17; H 3.87; N 8.98. 
2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-
6-methyl-2,3-dihydro-4H-chromen-4-one (3h). 
Yield 0.205 g, 75 %. Mp 113–114°C. 1H NMR
(400 MHz, DMSO-d6) δ 7.55 (s, 1H), 7.41 (d, J 
= 8.1 Hz, 1H), 7.03 (d, J = 8.1 Hz, 1H), 6.11 (t, J 
= 6.0 Hz, 1H), 3.21 (br. d, J = 6.2 Hz, 2H), 2.26 
(s, 3H), 2.18 – 2.06 (m, 1H), 1.06 (d, J = 6.2 Hz, 
2H), 0.90 – 0.77 (br. m, 2H). 13C NMR (125 
MHz, DMSO-d6) δ 187.1, 174.2, 172.4, 157.6, 
131.9, 131.5, 126.4, 121.7, 115.4, 70.4, 39.6, 
20.8, 7.9, 6.4 (2C). Anal. Calcd. for C15H14N2O3: 
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C 66.66; H 5.22; N 10.30. Found: C 66.71; H 
5.29; N 10.34. 
2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-
6-fluoro-2,3-dihydro-4H-chromen-4-one (3i). 
Yield 0.219 g, 80 %. Mp 93–95°C. 1H NMR (400 
MHz, DMSO-d6) δ 7.82 – 7.75 (m, 2H), 7.14 (d, 
J = 8.3 Hz, 1H), 6.19 (t, J = 6.6 Hz, 1H), 3.27 (d, 
J = 6.6 Hz, 2H), 2.19 – 2.08 (m, 1H), 1.06 (d, J = 
7.5 Hz, 2H), 0.86 – 0.83 (br. m, 2H). 13C NMR 
(125 MHz, DMSO-d6) δ 188.4, 174.9, 172.1, 
157.0 (d, JCF = 239 Hz), 155.5, 123.9 (d, , JCF = 
25 Hz), 121.3 (d, JCF = 6 Hz), 120.2 (d, JCF = 7 
Hz), 111.2 (d, JCF = 24 Hz), 70.5, 39.1, 7.7, 6.2 
(2C). Anal. Calcd. for C14H11FN2O3: C 61.31; H 
4.04; N 10.21. Found: 61.28; H 4.09; N 10.28. 
6-bromo-2-[3-(3-bromo-5-
fluorophenyl)-1,2,4-oxadiazol-5-yl]-2,3-
dihydro-4H-chromen-4-one (3j). Yield 0.398 g, 
85 %. Mp 171–172°C. 1H NMR (400 MHz, 
DMSO-d6) δ 7.93 (s, 1H), 7.87 – 7.85 (br. m, 
2H), 7.77 (br. d, J = 9.0 Hz, 2H), 7.18 (d, J = 8.9 
Hz, 1H), 6.37 (dd, J = 8.1, 5.1 Hz, 1H), 3.42 – 
3.38 (m, 2H). 13C NMR (125 MHz, DMSO-d6) δ 
188.3, 176.7, 166.4 (d, J = 3 Hz), 162.7 (d, J = 
250 Hz), 158.6, 139.4, 129.5 (d, J = 9 Hz), 128.7, 
126.5 (d, J = 1 Hz), 123.5 (d, J = 10 Hz), 122.8 
(d, J = 24 Hz), 122.7, 121.2, 114.7, 113.8 (d, JCF 
= 23 Hz), 70.9, 40.4. Anal. Calcd. for 
C17H9Br2FN2O3: C 43.62; H 1.94; N 5.98. Found: 
C 43.68; H 1.99; N 6.01. 
Results and discussion 
This work is devoted to the preparation of 
the small library of 2-(1,2,4-oxadiazol-5-yl)-2,3-
dihydro-4H-chromen-4-ones (3a–j) – promising 
derivatives for medicinal chemistry. For this 
purpose, CDI (carbonyldiimidazole)-mediated 
cyclocondensation of substituted 4-
oxochromane-2-carboxylic acids 1 and 
amidoximes 2 was performed (Scheme 1). 
 
 
Scheme 1. Synthesis of 2-(1,2,4-oxadiazol-5-yl)-2,3-dihydro-4H-chromen-4-ones
The reaction proceeded smoothly by 
heating the mixture of starting materials in the 
presence of CDI in DMF at 70°C for 1 h and gave 
the target products in 65–85% yield after a 
simple purification protocol by recrystallization. 
These mild reaction conditions are suitable for a 
wide range of substituents at both benzene and 
1,2,4-oxadiazole cores. The structures of 
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compounds obtained were confirmed by 1H 
NMR and 13C NMR experiments and elementary 
analysis. 
According to the literature data, common 
methods for the synthesis of 2-hetaryl-2,3-
dihydro-4H-chromen-4-ones rely on 
transformations of corresponding carbonyl 
compounds via the chalcone formation. On the 
other side, the synthetic application of C(2)-
substituted carboxylic acids 1 for the 
construction of the additional heterocyclic core 
was reported only once [21]. In particular, the 
known reaction of thiosemicarbazide with 
dihydrochromenone 1 (R1 = R2 = H) resulted in 
the formation of 2-(5-аmino-[1,3,4]thiadiazol-2-
yl)-4H-chromen-4-one that was studied as PTR1 
inhibitor and antiparasitic drug candidate [21]. 
Other examples included the preparation of 
unsaturated analogs of derivatives 3 – hydroxy-
2[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-
yl]chromones, which were synthesized from 
corresponding acids using the mixed anhydride 
method. The aforementioned chromones were 
evaluated as inhibitors of tyrosine kinases, and 
therefore can be used for cancer treatment, 
neuroprotection, and protection of skin's stress 
proteins [22]. These data allow us to anticipate 
that synthesized compounds 3 will find broad 
application in medicinal chemistry. Moreover, 
the introduction of fluorine atoms to chromone 
derivatives 3 was profitable to improve physico-
chemical properties of derivatives with increased 
metabolic stability and lipophilicity, and 
diminished idiosyncratic drug toxicity [23]. 
Conclusions 
The general and efficient approach for the 
synthesis of 2-(1,2,4-oxadiazol-5-yl)-2,3-
dihydro-4H-chromen-4-ones was reported. The 
methods relied on cyclocondensation of available 
4-oxochromane-2-carboxylic acids and 
amidoximes in DMF in the presence of CDI as an 
activating agent. This protocol allowed the 
combination of two potent pharmacophores 
(dihydro-4H-chromen-4-one and 1,2,4-
oxadiazole) and required simple purification 
steps to give ten representative examples of the 
title products in good to high yields (65–85%). 
We anticipate the proposed method and products 
to be useful in modern medicinal chemistry. 
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